Project Grant R01AI189353
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,314,470 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The Johns Hopkins University. The grant will fund research exploring the impact of gender-affirming hormone therapy on HIV viral dynamics and immune responses in transgender women. The project will leverage two cohorts of transgender women, including a cross-sectional cohort of 120 individuals and a clinical trial...
- This federal Project Grant award of $1,016,951 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to reverse the effector-to-memory transition at antiretroviral therapy initiation (ARTI) in order to impact the HIV reservoir and potentially achieve ART-free control. The award recipient, The University of Texas MD Anderson Cancer Center, will conduct proof-of-concept studies in a...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $439,088 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The project, led by Principal Investigator Dr. Daniel Lingwood, aims to mechanistically define how sex differences in hormones and circulating cytokines modulate B cell class switch recombination, a core immune...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $295,276 Project Grant to the University of Chicago under the Allergy and Infectious Diseases Research program (CFDA 93.855) on January 18, 2025. The grant supports a computational research project investigating the assembly and disassembly processes of the HIV-1 virus, including the budding of the immature virion, maturation of the viral core, and uncoating. The research aims to gain a mechanistic understanding of these...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $801,363 Project Grant to the New York Blood Center, Inc. The grant, awarded on December 16, 2024, will fund a study to understand the immune and behavioral responses of transgender women to the updated seasonal COVID-19 vaccines. The study aims to dissect the role of female sex hormones in enhancing immunity and understand the...
- This Project Grant award of $672,248 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research by The Johns Hopkins University to analyze the impact of sex, pregnancy, and aging on the HIV reservoir and immune responses in a cohort of individuals living with HIV in Uganda. The 5-year award, effective September 15, 2025, aims to: 1) examine how pregnancy affects the HIV reservoir and immunity, 2) assess HIV...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $859,992 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Yale University. The grant supports research on the molecular mechanisms underlying HIV-1 maturation and the effects of inhibitor compounds on this process. The research involves using advanced in situ cryo-electron microscopy techniques to visualize the structural transitions of HIV-1 Gag assemblies and capsid during...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $170,411 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to Brigham & Women's Hospital Inc. The grant, awarded on August 8, 2025, will provide mentorship to trainees and early career investigators in clinical studies and translational virology techniques related to HIV persistence, therapeutic interventions for sustained antiretroviral therapy-free HIV...
- This federal Project Grant award of $112,956.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Texas A&M University System Health Science Center to define the role of sex-specific traits in influencing the integration of immune and metabolic responses that impact infection susceptibility. The research will use the Drosophila melanogaster model to test the hypothesis that post-mating changes in...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $568,909 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Texas Health Science Center at Houston (UTHealth). The grant, titled "A Wastewater Approach to Viral Transmission, Evolution, and Ecology", aims to establish a framework for understanding and predicting viral dynamics at the community level. The project will integrate wastewater...
The University of Texas Health Science Center at Houston (UTHealth) received a Project Grant award of $2,461,651 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to study how the female sex hormone estrogen can modulate immunoglobulin G (IgG) glycosylation in people living with HIV on antiretroviral therapy. Specifically, the research will investigate whether estrogen can reverse the HIV-associated loss of IgG galactose, which has been linked to higher inflammation, HIV reservoir size, and viral rebound. The project period runs from August 18, 2025, to July 31, 2029, and builds on the researchers' previous findings published in Nature Communications.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.5m | 8/18/25 |